Measure 2.1

Objective area
Safe
Outcome area
Avoidance of overtreatment
Measure
Proportion of people with life-limiting illnesses who received potentially non-beneficial treatments at the end of life.
Population
People with life-limiting illnesses who died within the reference year.
Numerator
Number of people with life-limiting illnesses who died within the reference year and had at least one record of receiving a potentially non-beneficial treatment as an inpatient of a public hospital at the end of life. This includes cardiopulmonary resuscitation, intravenous feeding, mechanical ventilation, or initiation of chemotherapy or dialysis in the last 30 days of life (0 to 29 days inclusive), or receipt of chemotherapy in the last 15 days of life (0 to 14 days inclusive).
Denominator
Number of people with life-limiting illnesses who died within the reference year.
Computation
(Numerator ÷ Denominator) x 100
Disaggregation
State/Territory, Age, Sex, Socioeconomic area, Remoteness area, Cause of death, Potentially non-beneficial treatment. For more information see Data sources.
Source
AIHW National Integrated Health Service Information (NIHSI) linked data asset.
Definitions

People with life-limiting illnesses – all people who died in the reference year and had an underlying cause of death amenable to palliative care based on Murtagh et al. (2013) ) as shown in Table 2.1.2.

Table 2.1.2: Causes of death amenable to palliative care based on Murtagh et al. (2013)
Cause of deathICD-10 codes
Neoplasm (excludes benign neoplasms)C00-C97
Heart diseaseI00-I52
Cerebrovascular diseaseI60-I69
Renal diseaseN17, N18, N28
Liver diseaseK70-K77
Respiratory diseaseJ06-J18, J20-J22, J40-J47, J96
Neurodegenerative diseaseG10, G20, G35, G122, G903, G231
Alzheimer’s diseaseF01, F03
DementiaG30
SenilityR54
HIV/AIDSB20-B24

Potentially non-beneficial treatment – A treatment or intervention that is unlikely to prolong life or provide comfort at the end of life including the following treatments from the Australian Classification of Health Interventions Code:

Table 2.1.3: Non-beneficial treatment by Australian Classification of Health Intervention Codes

Non-beneficial treatment

Block description

Block extension

Block ext. description

Chemotherapy (receipt in the last 15 days of life or initiation in the last 30 days of life

Administration of pharmacological agent, antineoplastic agent

96196-00

Intra-arterial

Chemotherapy (receipt in the last 15 days of life or initiation in the last 30 days of life
Administration of pharmacological agent, antineoplastic agent

96197-00

Intramuscular

Chemotherapy (receipt in the last 15 days of life or initiation in the last 30 days of life
Administration of pharmacological agent, antineoplastic agent

96198-00

Intrathecal

Chemotherapy (receipt in the last 15 days of life or initiation in the last 30 days of life
Administration of pharmacological agent, antineoplastic agent

96199-00

Intravenous

Chemotherapy (receipt in the last 15 days of life or initiation in the last 30 days of life
Administration of pharmacological agent, antineoplastic agent

96200-00

Subcutaneous

Chemotherapy (receipt in the last 15 days of life or initiation in the last 30 days of life
Administration of pharmacological agent, antineoplastic agent

96201-00

Intracavitary

Chemotherapy (receipt in the last 15 days of life or initiation in the last 30 days of life
Administration of pharmacological agent, antineoplastic agent

96202-00

Enteral

Chemotherapy (receipt in the last 15 days of life or initiation in the last 30 days of life
Administration of pharmacological agent, antineoplastic agent

96203-00

Oral

Chemotherapy (receipt in the last 15 days of life or initiation in the last 30 days of life
Administration of pharmacological agent, antineoplastic agent

96205-00

Other

Chemotherapy (receipt in the last 15 days of life or initiation in the last 30 days of life
Administration of pharmacological agent, antineoplastic agent

96209-00

Loading of drug delivery device, antineoplastic agent

Cardiopulmonary resuscitation (in the last 30 days of life)

Therapeutic interventions on cardiovascular system

92052-00

Cardiopulmonary resuscitation

Artificial nutrition (in the last 30 days of life)

Administration of pharmacological agent, nutritional substance

96196-07

Intra-arterial

Artificial nutrition (in the last 30 days of life)
Administration of pharmacological agent, nutritional substance

96197-07

Intramuscular

Artificial nutrition (in the last 30 days of life)
Administration of pharmacological agent, nutritional substance


 96198-07

Intrathecal

Artificial nutrition (in the last 30 days of life)
Administration of pharmacological agent, nutritional substance

96199-07

Intravenous

Artificial nutrition (in the last 30 days of life)
Administration of pharmacological agent, nutritional substance

96200-07

Subcutaneous

Artificial nutrition (in the last 30 days of life)
Administration of pharmacological agent, nutritional substance

96201-07

Intracavitary

Artificial nutrition (in the last 30 days of life)
Administration of pharmacological agent, nutritional substance

96202-07

Enteral

Artificial nutrition (in the last 30 days of life)
Administration of pharmacological agent, nutritional substance

96203-07

Oral

Artificial nutrition (in the last 30 days of life)
Administration of pharmacological agent, nutritional substance

96205-07

Other

Artificial nutrition (in the last 30 days of life)
Administration of pharmacological agent, nutritional substance

96209-07

Loading of drug delivery device, nutritional substance

Mechanical ventilation (in the last 30 days of life)

Management of continuous ventilatory support

13882-00

24 hours or less

Mechanical ventilation (in the last 30 days of life)
Management of continuous ventilatory support

13882-01

More than 24 but less than 96 hours

Mechanical ventilation (in the last 30 days of life)
Management of continuous ventilatory support

13882-02

96 hours or more

Mechanical ventilation (in the last 30 days of life)

Management of non-invasive ventilatory support

92209-00

24 hours or less

Mechanical ventilation (in the last 30 days of life)
Management of non-invasive ventilatory support

92209-01

More than 24 but less than 96 hours

Mechanical ventilation (in the last 30 days of life)
Management of non-invasive ventilatory support

92209-02

96 hours or more

Dialysis (initiation in the last 30 days of life)

Peritoneal dialysis

13100-06

Peritoneal dialysis, short term

Dialysis (initiation in the last 30 days of life)
Peritoneal dialysis

13100-07

Intermittent peritoneal dialysis, long term

Dialysis (initiation in the last 30 days of life)
Peritoneal dialysis

13100-08

Continuous peritoneal dialysis, long term

Dialysis (initiation in the last 30 days of life)

Haemodialysis

13100-00

Haemodialysis

Dialysis (initiation in the last 30 days of life)
Haemodialysis

13100-01

Intermittent haemofiltration

Dialysis (initiation in the last 30 days of life)
Haemodialysis

13100-02

Continuous haemofiltration

Dialysis (initiation in the last 30 days of life)
Haemodialysis

13100-03

Intermittent haemodiafiltration

Dialysis (initiation in the last 30 days of life)
Haemodialysis

13100-04

Continuous haemodiafiltration

Dialysis (initiation in the last 30 days of life)
Haemodialysis

13100-05

Haemoperfusion

Notes
  1. Identifying overtreatment using administrative data is challenging as the data do not capture the nuance at the time of treating, such as treatment appropriateness, care intent, life expectancy, patient functionality, patient and family preferences, and physician-patient interactions. Furthermore, end of life trajectories are inherently uncertain. It can be very difficult for clinicians to predict time to death, and they may not know that a treatment is non-beneficial at the time of treating. Given the uncertainty of the circumstances at the time of treating and the social and ethical pressures that exist, a certain level of potentially non-beneficial treatments will likely always be present but reducing their occurrence should be an aim of improving the quality of palliative care in Australia.
  2. There is currently no complete national data on receipt of potentially non-beneficial treatments for people with life-limiting illnesses. The NIHSI linked data asset is the only available national data that identifies inpatient procedures and cause-specific outcomes. However, this data collection does not present a complete picture of health service use, as it excludes hospital data from Western Australia and the Northern Territory, and all private hospitals nationally for this analysis, for the reference period. It omits services received by patients in specialised palliative care units in private hospitals/ facilities. For more information see Data sources.